GlassScriptPhysician profile
Cathaline L Pearson
NPI 1508821281
$8,620.85
in general payments reported to CMS, 2019-2025
46 companies · $17.70 in 2025
The $17.70 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,726 · 2022: $2,326 · 2023: $2,824 · 2024: $727 · 2025: $17.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,484 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,483.75 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,632.59 | 2021-2025 | |
| Novo Nordisk INC | $1,134.62 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $717.54 | 2021-2024 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $623.49 | 2021-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $506.69 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Astellas Pharma US INC | $476.76 | 2021-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $441.66 | 2021-2024 | Xarelto |
| Amgen INC. | $414.62 | 2021-2023 | Otezla, Repatha |
| Pfizer INC. | $296.22 | 2021-2024 | |
| Glaxosmithkline, LLC. | $223.17 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $208.70 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $152.73 | 2021-2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $135.88 | 2021 | |
| Sanofi-Aventis U.S. LLC | $134.55 | 2021 | |
| Exact Sciences Corporation | $130.96 | 2023 | Cologuard Collection Kit |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cathaline Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.